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Next steps: Evaluation of scFv-toxin binding affinity
Soluble scFv fragments are to be expressed by E. coli for affinity studies using isothermal titration
calorimetry (ITC) or surface plasmon resonance (SPR). We intend to expand our investigation of scFv cross-
reactivity to PLA2s from venoms of other snake species. We hope to develop human scFvs that may broadly
neutralize snake venom PLA2s across snake genera.
Addressing the problem of immunogenic antivenoms
Snakebite is one of the world’s most neglected tropical diseases, with an estimated 5.5 million bites per
year, resulting in 125.000 deaths [1]. The only current treatment for snakebite envenoming is antiserum
derived from the blood of immunized mammals (typically horses) [2]. These antisera are expensive to
produce and carry a high risk of causing hyper-allergic reactions in human recipients due to their
heterologous origin [3]. Here we report the discovery of human scFvs against Aipysurus laevis toxins.
Composition of A. laevis venom according to protein families,
expressed as percentages of the total protein content [4]:
3FTx: three-finger toxin
PLA2: phospholipase A2
CRISP: cysteine-rich secretory protein
CCM: complement control module
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Selected monoclonal phages expressing scFv were investigated by ELISA against Biotinylated-PLA2,
PLA2, Streptavidin, HSA, & PBS. Top: Top 24 of 288 clones from first selection. Bottom: top 20 of 86
clones from second selection.
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Polyclonal ELISA of four different panning rounds performed in the phage display selection using
Tomlinson Library I & J against biotinylated-PLA2.
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Selection using human scFv displaying phages
Panning rounds using Tomlinson libraries
Isolated ssDNA from twelve
promising binders was
sequenced. Two of these
sequences were modeled using
SwissModel [6].
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